News
RHHBY
51.42
-0.33%
-0.17
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
NASDAQ · 2d ago
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
NASDAQ · 2d ago
BUZZ-Outlook Therapeutics plunges after FDA rejects eye drug for third time
Reuters · 2d ago
What's Going On With Royalty Pharma Stock Wednesday?
Benzinga · 12/31/2025 15:47
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report
Seeking Alpha · 12/31/2025 13:22
TG Therapeutics: What Wall Street Isn't Telling You
Seeking Alpha · 12/30/2025 16:00
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
Seeking Alpha · 12/30/2025 13:57
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics
NASDAQ · 12/30/2025 02:15
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi
Seeking Alpha · 12/29/2025 22:13
Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
TipRanks · 12/29/2025 21:45
Weekly Report: what happened at RHHBY last week (1222-1226)?
Weekly Report · 12/29/2025 10:33
Medicare pilot programs aim to reduce prescription drug spend
Seeking Alpha · 12/24/2025 14:29
Caris Life Sciences: Stronger Fundamentals, Same Conclusion
Seeking Alpha · 12/24/2025 13:00
Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Seeking Alpha · 12/23/2025 23:08
Franklin Income Focus ETF Experiences Big Outflow
NASDAQ · 12/23/2025 16:07
Genentech's subcutaneous Lunsumio gains FDA approval
Seeking Alpha · 12/23/2025 16:00
BioMarin: Amicus Buyout Sparks My Enthusiasm
Seeking Alpha · 12/22/2025 20:15
Trump Trade: Trump strikes deals with nine drugmakers to cut prices
TipRanks · 12/22/2025 15:25
US Medicaid Program Will Hit Swiss Wallets Hard, Roche CEO Says
Benzinga · 12/22/2025 13:43
Genentech Receives FDA Approval for Lymphoma Treatment
Dow Jones · 12/22/2025 12:24
More
Webull provides a variety of real-time RHHBY stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.